XORTX Therapeutics (XRTX) Other Non-Current Liabilities (2020 - 2025)
XORTX Therapeutics' (XRTX) quarterly Other Non-Current Liabilities came in at $24746.0 in Q3 2025, little changed YoY from $24746.0 in Q3 2024, and little changed on a QoQ basis from $24746.0 in Q2 2025.
XORTX Therapeutics (XRTX) Other Non-Current Liabilities (2020 - 2025) Analysis & Trends
XORTX Therapeutics (XRTX) has 6 years of Other Non-Current Liabilities data on file, last reported at $24746.0 in Q3 2025.
- Quarterly Other Non-Current Liabilities changed 0.0% year-over-year to $24746.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $24746.0 (changed 0.0% YoY) and the FY2024 annual result came in at $24746.0, changed 0.0% from the prior year.
- Other Non-Current Liabilities held at $24746.0 in Q3 2025, from $24746.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $25610.2 in Q3 2021 to a low of $23749.8 in Q4 2022.
- A 5-year average of $24858.6 and a median of $24746.0 in 2023 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities decreased 7.14% — and 2023, when it advanced 4.19%.
- Tracing XRTX's Other Non-Current Liabilities over 5 years: stood at $25575.6 in 2021, then retreated by 7.14% to $23749.8 in 2022, then gained by 4.19% to $24746.0 in 2023, then changed by 0.0% to $24746.0 in 2024, then changed by 0.0% to $24746.0 in 2025.
- The last three Other Non-Current Liabilities figures came in at $24746.0 (Q3 2025), $24746.0 (Q2 2025), and $24746.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.07 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.92 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn |
| 4 | Moderna | 58.86 Bn | 53.72 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.88 Bn | 9.49 Bn | 668.28 Mn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - |
| 10 | XORTX Therapeutics | 2.84 Mn | 2.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 24,746.00 |
| Jun 30, 2025 | 24,746.00 |
| Mar 31, 2025 | 24,746.00 |
| Dec 31, 2024 | 24,746.00 |
| Sep 30, 2024 | 24,746.00 |
| Jun 30, 2024 | 24,746.00 |
| Mar 31, 2024 | 24,746.00 |
| Dec 31, 2023 | 24,746.00 |
| Sep 30, 2023 | 24,746.00 |
| Jun 30, 2023 | 24,746.00 |
| Mar 31, 2023 | 24,746.00 |
| Dec 31, 2022 | 23,749.83 |
| Sep 30, 2022 | 24,718.37 |
| Jun 30, 2022 | 25,285.57 |
| Mar 31, 2022 | 25,451.11 |
| Dec 31, 2021 | 25,575.57 |
| Sep 30, 2021 | 25,610.17 |
| Dec 31, 2020 | 24,728.31 |